FDA Withdraws Nod to 27 Ranbaxy Laboratories ANDAs
Published: Aug 24, 2012
The US Food and Drug Administration has withdrawn approval given to 27 generic products of Ranbaxy Laboratories. In a letter posted on its website, the regulator said Ranbaxy had requested for withdrawal of approval to 27 of its abbreviated new drug applications (ANDAs) under a consent decree it entered in January this year. The 27 drugs include certain antibiotic capsules and oral suspensions, and drugs for fungal infection and diabetes. A Ranbaxy spokesperson said these products do not pertain to the current business of the company and hence will have negligible impact.